Literature DB >> 17594090

[99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results.

Theodosia Maina1, Anastasia Nikolopoulou, Eleni Stathopoulou, Athanassios S Galanis, Paul Cordopatis, Berthold A Nock.   

Abstract

PURPOSE: The aim of this study was to evaluate the applicability of [(99m)Tc]Demotensin 5 and 6 [Formula: see text] in the targeted diagnostic imaging of neurotensin subtype 1 receptor (NTS1-R)-expressing tumours.
METHODS: Labelling of Demotensin 5 and 6 with (99m)Tc was conducted by brief incubation with (99m)TcO(4) (-), SnCl(2) and citrate anions in alkaline medium at ambient temperature. Affinities of conjugates for the NTS1-R were determined by competition binding experiments in WiDr cell membranes using [(125)I-Tyr(3)]NT as the radioligand. Saturation binding assays were conducted for [(99m)Tc/(99g)Tc]Demotensin 6 in WiDr cell membranes. Internalisation of [(99m)Tc]Demotensin 5 and 6 was studied at 37 degrees C in WiDr cells. Biodistribution of [(99m)Tc]Demotensin 5 and 6 was performed in female Swiss nu/nu mice bearing human WiDr xenografts.
RESULTS: Unlabelled conjugates showed a high affinity for the human NTS1-R (Demotensin 5 IC(50)=0.03+/-0.01 nM; Demotensin 6 IC(50)=0.08+/-0.02 nM), while high affinity was also exhibited by (radio)metallated [(99m)Tc/(99g)Tc]Demotensin 6 (K (d)=0.13+/-0.01 nM). [(99m)Tc]Demotensin 5 and 6 internalised rapidly and specifically in WiDr cells. After injection in WiDr tumour-bearing mice, radiopeptides, and especially the doubly stabilised [(99m)Tc]Demotensin 6, showed NTS1-R-mediated uptake in the intestines and in the implanted tumour (4.30+/-0.45%ID/g at 1 h post injection) and rapid renal excretion from non-target tissues into the urine.
CONCLUSION: [(99m)Tc]Demotensin 6 shows a favourable preclinical profile and further testing in patients is warranted to monitor its eventual applicability as a radiotracer in the diagnostic imaging of NTS1-R-positive tumours.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594090     DOI: 10.1007/s00259-007-0489-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  31 in total

1.  Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas.

Authors:  J C Reubi; B Waser; J C Schaer; J A Laissue
Journal:  Int J Cancer       Date:  1999-07-19       Impact factor: 7.396

Review 2.  Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N.

Authors:  P Kitabgi; F De Nadai; C Rovère; J N Bidard
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

3.  Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments.

Authors:  J J Maoret; D Pospaï; C Rouyer-Fessard; A Couvineau; C Laboisse; T Voisin; M Laburthe
Journal:  Biochem Biophys Res Commun       Date:  1994-08-30       Impact factor: 3.575

Review 4.  Neurotensin and neurotensin receptors.

Authors:  J P Vincent; J Mazella; P Kitabgi
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

Review 5.  Candidates for peptide receptor radiotherapy today and in the future.

Authors:  Jean Claude Reubi; Helmut R Mäcke; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

6.  Novel 99mTc-labeled neurotensin analogues with optimized biodistribution properties.

Authors:  Veronique Maes; Elisa Garcia-Garayoa; Peter Bläuenstein; Dirk Tourwé
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

7.  Gut peptide receptor expression in human pancreatic cancers.

Authors:  R A Ehlers; Sh Kim; Y Zhang; R T Ethridge; C Murrilo; M R Hellmich; D B Evans; C M Townsend; B Mark Evers
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

Review 8.  Somatostatin receptor imaging.

Authors:  Dik J Kwekkeboom; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

9.  Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.

Authors:  Samuel Achilefu; Ananthacari Srinivasan; Michelle A Schmidt; Hermo N Jimenez; Joseph E Bugaj; Jack L Erion
Journal:  J Med Chem       Date:  2003-07-17       Impact factor: 7.446

10.  Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.

Authors:  Franz Buchegger; Florent Bonvin; Marek Kosinski; Andreas O Schaffland; John Prior; Jean C Reubi; Peter Bläuenstein; Dirk Tourwé; Elisa García Garayoa; Angelika Bischof Delaloye
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

View more
  8 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

2.  Synthesis of a (68)ga-labeled peptoid-Peptide hybrid for imaging of neurotensin receptor expression in vivo.

Authors:  Simone Maschauer; Jürgen Einsiedel; Carsten Hocke; Harald Hübner; Torsten Kuwert; Peter Gmeiner; Olaf Prante
Journal:  ACS Med Chem Lett       Date:  2010-05-21       Impact factor: 4.345

3.  Investigation of the Biological Impact of Charge Distribution on a NTR1-Targeted Peptide.

Authors:  Yinnong Jia; Wenting Zhang; Wei Fan; Susan Brusnahan; Jered Garrison
Journal:  Bioconjug Chem       Date:  2016-10-21       Impact factor: 4.774

4.  Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.

Authors:  Yinnong Jia; Wen Shi; Zhengyuan Zhou; Nilesh K Wagh; Wei Fan; Susan K Brusnahan; Jered C Garrison
Journal:  Nucl Med Biol       Date:  2015-07-29       Impact factor: 2.408

5.  Radiolabeled peptides: valuable tools for the detection and treatment of cancer.

Authors:  M Fani; H R Maecke; S M Okarvi
Journal:  Theranostics       Date:  2012-05-16       Impact factor: 11.556

6.  Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors.

Authors:  Lisa Schindler; Jutta Moosbauer; Daniel Schmidt; Thilo Spruss; Lukas Grätz; Steffen Lüdeke; Frank Hofheinz; Sebastian Meister; Bernd Echtenacher; Günther Bernhardt; Jens Pietzsch; Dirk Hellwig; Max Keller
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

7.  In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study.

Authors:  Simone Maschauer; Tina Ruckdeschel; Philipp Tripal; Roland Haubner; Jürgen Einsiedel; Harald Hübner; Peter Gmeiner; Torsten Kuwert; Olaf Prante
Journal:  Pharmaceuticals (Basel)       Date:  2014-04-16

8.  Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors.

Authors:  Panagiotis Kanellopoulos; Berthold A Nock; Eric P Krenning; Theodosia Maina
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.